BioInvent Rises on Post Blood Thinner Savings: Stockholm Mover

BioInvent International AB rose as much as 6.8 percent in Stockholm trading as the biotechnology company said it will start trade union talks to cut 21 jobs after it halted development of an anti-thrombotic drug candidate.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.